<?xml version="1.0" encoding="UTF-8"?>
<paload id="" version="">
	<toplevel>
		<routedMedId>153521</routedMedId>
		<routedMedName>Actemra intravenous</routedMedName>
		<routedGenericName>tocilizumab intravenous</routedGenericName>
		<etcIds>
			<etc_id>6210</etc_id>
		</etcIds>
		<medIds>
			<medId>560256</medId>
			<medId>560257</medId>
			<medId>560258</medId>
			<medId>580144</medId>
		</medIds>
	</toplevel>
	<diagnoses>
		<diagnosis>
			<fqn>Rheumatoid Arthritis-moderate to severe</fqn>
			<age>
				<ageRangeType>nocode</ageRangeType>
				<ageRangeMin>18</ageRangeMin>
				<ageRangeMax/>
				<ageRangeUnit>y</ageRangeUnit>
				<ageDesc/>
			</age>
			<gender>nocode</gender>
			<icd9>22.2805</icd9>
			<symbolic>Actemra-RA</symbolic>
			<rating>labeledDx</rating>
			<genotype>
				<name></name>
			</genotype>
			<polymorphism>
				<name></name>
			</polymorphism>
			<subtype_name>
				<name></name>
			</subtype_name>
			<severity>
				<name></name>
				<code></code>
				<dur></dur>
				<durUnit>nocode</durUnit>
			</severity>
			<prescribers>
				<prescriber>
					<name>Rheumatologist</name>
					<code>207RR0500X</code>
				</prescriber>
			</prescribers>
			<comorbidities>
				<comorbidity>
					<name/>
					<code/>
					<severity_name/>
					<severity_code/>
					<subtype_name></subtype_name>
					<inclusion_exclusion>inclusion</inclusion_exclusion>
					<dur></dur>
					<durUnit>nocode</durUnit>
				</comorbidity>
			</comorbidities>
			<concurrenttherapy>
			  <criteriaSet>
			    <patientHxType>
			      <typeName>nocode</typeName>
			      <treatment>
			        <treatmentLine>
			          <interventionType>drug</interventionType>
			          <name></name>
			          <codeValues/>
			        </treatmentLine>
			      </treatment>
			    </patientHxType>
			    <preferredTherapy>
			      <treatment>
			        <dosing></dosing>
			        <rating>atherapy</rating>
			        <treatmentLine>
			          <interventionType>drug</interventionType>
			          <name/>
			          <codeValues/>
			          <durModifier>nocode</durModifier>
			          <dur/>
			          <durUnit>nocode</durUnit>
			          <timeFrame>nocode</timeFrame>
			        </treatmentLine>
			      </treatment>
			    </preferredTherapy>
			  </criteriaSet>
			</concurrenttherapy>
			<triedtherapy>
				<criteriaSet>
					<patientHxType>
						<typeName>nocode</typeName>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
							</treatmentLine>
						</treatment>
					</patientHxType>
					<preferredTherapy>
						<numRequired>any</numRequired>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
								<durModifier>nocode</durModifier>
								<dur/>
								<durUnit>nocode</durUnit>
								<timeFrame>nocode</timeFrame>
								<numRequired>any</numRequired>
							</treatmentLine>
							<mustBeIneligible>false</mustBeIneligible>
							<documentationRequired>false</documentationRequired>
						</treatment>
					</preferredTherapy>
				</criteriaSet>
			</triedtherapy>
			<triedTherapyExclusion>
				<criteriaSet>
					<excludedTherapy>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
								<timeFrame>nocode</timeFrame>
							</treatmentLine>
						</treatment>
					</excludedTherapy>
				</criteriaSet>
			</triedTherapyExclusion>
		  <concurrentTherapyExclusion>
		    <criteriaSet>  
		      <excludedTherapy>
		        <treatment>  
		          <treatmentLine> 
		            <option>WITH</option>
		            <interventionType>drug</interventionType>
		            <name/>
		            <codeValues/>
		            <selectedListName/>
		            <selectedListClassCode/>
		          </treatmentLine>
		        </treatment>
		      </excludedTherapy>
		    </criteriaSet>
		  </concurrentTherapyExclusion>
			<dosing>
				<text/>
			</dosing>
			<instructions>
				<instruction/>
			</instructions>
			<qlimits>
				<qlimit>
					<medId/>
					<initPerDayDesc/>
					<initPerIntervalDesc/>
					<renewPerDayDesc/>
					<renewPerIntervalDesc/>
				</qlimit>
			</qlimits>
			<durations>
				<initialDur>
					<dur/>
					<durUnit>nocode</durUnit>
				</initialDur>
				<renewalDur>
					<dur/>
					<durUnit>nocode</durUnit>
				</renewalDur>
				<overallMax>
					<dur/>
					<durUnit>nocode</durUnit>
				</overallMax>
			</durations>
			<references>
				<reference>Actemra (tocilizumab) injection, for intravenous infusion. Physician Prescribing Information [Internet] Genentech, Inc. 2013 Oct Accessed at: http://www.actemra.com/. [created 2010; accessed 2013 Dec 3]</reference>
				<reference>Furst DE, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012. Annals of the Rheumatic Diseases 2013;72 Suppl 2:ii2-ii34. DOI: 10.1136/annrheumdis-2013-203348.</reference>
				<reference>Schoels MM, et al. Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement. Annals of the Rheumatic Diseases 2013;72(4):583-9. DOI: 10.1136/annrheumdis-2012-202470.</reference>
				<reference>Ash Z, Emery P. The role of tocilizumab in the management of rheumatoid arthritis. Expert Opinion on Biological Therapy 2012;12(9):1277-89. DOI: 10.1517/14712598.2012.707178.</reference>
				<reference>Smolen JS, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Annals of the Rheumatic Diseases 2010;69(6):964-75. DOI: 10.1136/ard.2009.126532. (Reaffirmed 2013 Nov)</reference>
				<reference>Tocilizumab for the treatment of rheumatoid arthritis (rapid review of technology appraisal guidance 198). NICE Technology Appraisal TA247 [Internet] National Institute for Health and Clinical Excellence. 2012 Feb Accessed at: http://guidance.nice.org.uk/. [accessed 2013 Oct 3]</reference>
				<reference>Smolen JS, et al. Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. Annals of the Rheumatic Diseases 2013;72(4):482-92. DOI: 10.1136/annrheumdis-2012-202469.</reference>
				<reference>Nam JL, et al. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Annals of the Rheumatic Diseases 2010;69(6):976-86. DOI: 10.1136/ard.2009.126573.</reference>
				<reference>Singh JA, Beg S, Lopez-Olivo MA. Tocilizumab for rheumatoid arthritis. Cochrane Database of Systematic Reviews 2010, Issue 7. Art. No.: CD008331. DOI: 10.1002/14651858.CD008331.pub2.</reference>
				<reference>Navarro-Millan I, Singh JA, Curtis JR. Systematic review of tocilizumab for rheumatoid arthritis: a new biologic agent targeting the interleukin-6 receptor. Clinical Therapeutics 2012;34(4):788-802.e3. DOI: 10.1016/j.clinthera.2012.02.014.</reference>
				<reference>Jones G, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Annals of the Rheumatic Diseases 2010;69(1):88-96. DOI: 10.1136/ard.2008.105197.</reference>
				<reference>Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J. Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. Annals of the Rheumatic Diseases 2009;68(10):1580-4. DOI: 10.1136/ard.2008.092866.</reference>
				<reference>Gabay C, et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet 2013;381(9877):1541-50. DOI: 10.1016/S0140-6736(13)60250-0.</reference>
				<reference>Nishimoto N, Ito K, Takagi N. Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions. Modern Rheumatology 2010;20(3):222-32. DOI: 10.1007/s10165-010-0279-5.</reference>
				<reference>An MM, Zou Z, Shen H, Zhang JD, Cao YB, Jiang YY. The addition of tocilizumab to DMARD therapy for rheumatoid arthritis: a meta-analysis of randomized controlled trials. European Journal of Clinical Pharmacology 2010;66(1):49-59. DOI: 10.1007/s00228-009-0754-0.</reference>
				<reference>Buch MH. Sequential use of biologic therapy in rheumatoid arthritis. Current Opinion in Rheumatology 2010;22(3):321-9. DOI: 10.1097/BOR.0b013e328337bd01.</reference>
				<reference>Nakashima Y, et al. Clinical evaluation of tocilizumab for patients with active rheumatoid arthritis refractory to anti-TNF biologics: tocilizumab in combination with methotrexate. Modern Rheumatology 2010;20(4):343-52. DOI: 10.1007/s10165-010-0290-x.</reference>
				<reference>Yazici Y, et al. Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study. Annals of the Rheumatic Diseases 2012;71(2):198-205. DOI: 10.1136/ard.2010.148700.</reference>
				<reference>Burmester GR, Feist E, Kellner H, Braun J, Iking-Konert C, Rubbert-Roth A. Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA). Annals of the Rheumatic Diseases 2011;70(5):755-9. DOI: 10.1136/ard.2010.139725.</reference>
				<reference>Singh JA, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database of Systematic Reviews 2011, (verified by Cochrane 2013 Feb), Issue 2. Art. No.: CD008794. DOI: 10.1002/14651858.CD008794.pub2.</reference>
				<reference>Campbell L, Chen C, Bhagat SS, Parker RA, Ostor AJ. Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials. Rheumatology 2011;50(3):552-62. DOI: 10.1093/rheumatology/keq343.</reference>
				<reference>Gout T, Ostor AJ, Nisar MK. Lower gastrointestinal perforation in rheumatoid arthritis patients treated with conventional DMARDs or tocilizumab: a systematic literature review. Clinical Rheumatology 2011;30(11):1471-4. DOI: 10.1007/s10067-011-1827-x.</reference>
				<reference>Bombardier C, et al. Canadian Rheumatology Association recommendations for the pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs: part II safety. Journal of Rheumatology 2012;39(8):1583-602. DOI: 10.3899/jrheum.120165. (Reaffirmed 2013 Nov)</reference>
			</references>
			<precautions>
				<precaution>
					<text/>
					<severity/>
				</precaution>
			</precautions>
			<alternatives>
			</alternatives>
		</diagnosis>
		<diagnosis>
			<fqn>Juvenile Idiopathic Arthritis</fqn>
			<age>
				<ageRangeType>range</ageRangeType>
				<ageRangeMin>2</ageRangeMin>
				<ageRangeMax>17</ageRangeMax>
				<ageRangeUnit>y</ageRangeUnit>
				<ageDesc/>
			</age>
			<gender>nocode</gender>
			<icd9>22.14082</icd9>
			<symbolic>Actemra-JIA</symbolic>
			<rating>labeledDx</rating>
			<genotype>
				<name/>
			</genotype>
			<polymorphism>
				<name/>
			</polymorphism>
			<subtype_name>
				<name/>
			</subtype_name>
			<severity>
				<name/>
				<code/>
				<dur/>
				<durUnit>nocode</durUnit>
			</severity>
			<prescribers>
				<prescriber>
					<name>Pediatric Rheumatology</name>
					<code>2080P0216X</code>
				</prescriber>
			</prescribers>
			<comorbidities>
				<comorbidity>
					<name/>
					<code/>
					<severity_name/>
					<severity_code/>
					<subtype_name/>
					<inclusion_exclusion>inclusion</inclusion_exclusion>
					<dur/>
					<durUnit>nocode</durUnit>
				</comorbidity>
			</comorbidities>
			<concurrenttherapy>
				<criteriaSet>
					<patientHxType>
						<typeName>nocode</typeName>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
							</treatmentLine>
						</treatment>
					</patientHxType>
					<preferredTherapy>
						<treatment>
							<dosing/>
							<rating>rtherapy</rating>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
								<durModifier>nocode</durModifier>
								<dur/>
								<durUnit>nocode</durUnit>
								<timeFrame>nocode</timeFrame>
							</treatmentLine>
						</treatment>
					</preferredTherapy>
				</criteriaSet>
			</concurrenttherapy>
			<triedtherapy>
				<criteriaSet>
					<patientHxType>
						<typeName>all</typeName>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
							</treatmentLine>
						</treatment>
					</patientHxType>
					<preferredTherapy>
						<numRequired>any</numRequired>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
								<durModifier>nocode</durModifier>
								<dur/>
								<durUnit>nocode</durUnit>
								<timeFrame>nocode</timeFrame>
								<numRequired>any</numRequired>
							</treatmentLine>
							<mustBeIneligible>false</mustBeIneligible>
							<documentationRequired>false</documentationRequired>
						</treatment>
					</preferredTherapy>
				</criteriaSet>
			</triedtherapy>
			<triedTherapyExclusion>
				<criteriaSet>
					<excludedTherapy>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
								<timeFrame>nocode</timeFrame>
							</treatmentLine>
						</treatment>
					</excludedTherapy>
				</criteriaSet>
			</triedTherapyExclusion>
			<concurrentTherapyExclusion>
				<criteriaSet>
					<excludedTherapy>
						<treatment>
							<treatmentLine>
								<option>WITH</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
							</treatmentLine>
						</treatment>
					</excludedTherapy>
				</criteriaSet>
			</concurrentTherapyExclusion>
			<dosing>
				<text/>
			</dosing>
			<instructions>
				<instruction/>
			</instructions>
			<qlimits>
				<qlimit>
					<medId/>
					<initPerDayDesc/>
					<initPerIntervalDesc/>
					<renewPerDayDesc/>
					<renewPerIntervalDesc/>
				</qlimit>
			</qlimits>
			<durations>
				<initialDur>
					<dur/>
					<durUnit>nocode</durUnit>
				</initialDur>
				<renewalDur>
					<dur/>
					<durUnit>nocode</durUnit>
				</renewalDur>
				<overallMax>
					<dur/>
					<durUnit>nocode</durUnit>
				</overallMax>
			</durations>
			<references>
				<reference> Actemra (tocilizumab) injection, for intravenous infusion. Physician Prescribing Information [Internet] Genentech, Inc. 2013 Oct Accessed at: http://www.actemra.com/. [created 2010; accessed 2013 Dec 3]</reference>
				<reference>Furst DE, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012. Annals of the Rheumatic Diseases 2013;72 Suppl 2:ii2-ii34. DOI: 10.1136/annrheumdis-2013-203348.</reference>
				<reference>Schoels MM, et al. Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement. Annals of the Rheumatic Diseases 2013;72(4):583-9. DOI: 10.1136/annrheumdis-2012-202470.</reference>
				<reference>Tocilizumab (Actemra - Hoffmann-La Roche) New indication: arthritis, systemic juvenile idiopathic. CEDC final recommendation [Internet] Canadian Agency for Drugs and Technologies in Health. 2012 Jul Accessed at: http://www.cadth.ca/en/products/cdr/cdr-overview. [accessed 2013 Oct 7]</reference>
				<reference>Tocilizumab for the treatment of systemic juvenile idiopathic arthritis. NICE Technology Appraisal TA238 [Internet] National Institute for Health and Clinical Excellence. 2011 Dec Accessed at: http://guidance.nice.org.uk/. [accessed 2013 Oct 3]</reference>
				<reference>DeWitt EM, et al. Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis. Arthritis Care &amp; Research 2012;64(7):1001-10. DOI: 10.1002/acr.21625.</reference>
				<reference>Herlin T. Tocilizumab for the treatment of systemic juvenile idiopathic arthritis. Expert Review of Clinical Immunology 2012;8(6):517-25. DOI: 10.1586/eci.12.49.</reference>
				<reference>De Benedetti F, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. New England Journal of Medicine 2012;367(25):2385-95. DOI: 10.1056/NEJMoa1112802.</reference>
				<reference>Beukelman T, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care &amp; Research 2011;63(4):465-82. DOI: 10.1002/acr.20460. (Reaffirmed 2013 Nov)</reference>
				<reference>Singh JA, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database of Systematic Reviews 2011, (verified by Cochrane 2013 Feb), Issue 2. Art. No.: CD008794. DOI: 10.1002/14651858.CD008794.pub2.</reference>
				<reference>Campbell L, Chen C, Bhagat SS, Parker RA, Ostor AJ. Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials. Rheumatology 2011;50(3):552-62. DOI: 10.1093/rheumatology/keq343.</reference>
				<reference>Gout T, Ostor AJ, Nisar MK. Lower gastrointestinal perforation in rheumatoid arthritis patients treated with conventional DMARDs or tocilizumab: a systematic literature review. Clinical Rheumatology 2011;30(11):1471-4. DOI: 10.1007/s10067-011-1827-x.</reference>
				<reference>Bombardier C, et al. Canadian Rheumatology Association recommendations for the pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs: part II safety. Journal of Rheumatology 2012;39(8):1583-602. DOI: 10.3899/jrheum.120165. (Reaffirmed 2013 Nov)</reference>
			</references>
			<precautions>
				<precaution>
					<text/>
					<severity/>
				</precaution>
			</precautions>
			<alternatives>
			</alternatives>
		</diagnosis>
		<diagnosis>
			<fqn>Ankylosing Spondylitis-inconclusive or non-supportive evidence</fqn>
			<age>
				<ageRangeType>nocode</ageRangeType>
				<ageRangeMin/>
				<ageRangeMax/>
				<ageRangeUnit>nocode</ageRangeUnit>
				<ageDesc/>
			</age>
			<gender>nocode</gender>
			<icd9>22.2827</icd9>
			<symbolic/>
			<rating>recommendedDx</rating>
			<genotype>
				<name/>
			</genotype>
			<polymorphism>
				<name/>
			</polymorphism>
			<subtype_name>
				<name/>
			</subtype_name>
			<severity>
				<name/>
				<code/>
				<dur/>
				<durUnit>nocode</durUnit>
			</severity>
			<prescribers>
				<prescriber>
					<name/>
					<code/>
				</prescriber>
			</prescribers>
			<comorbidities>
				<comorbidity>
					<name/>
					<code/>
					<severity_name/>
					<severity_code/>
					<subtype_name/>
					<inclusion_exclusion>inclusion</inclusion_exclusion>
					<dur/>
					<durUnit>nocode</durUnit>
				</comorbidity>
			</comorbidities>
			<concurrenttherapy>
				<criteriaSet>
					<patientHxType>
						<typeName>nocode</typeName>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
							</treatmentLine>
						</treatment>
					</patientHxType>
					<preferredTherapy>
						<treatment>
							<dosing/>
							<rating>rtherapy</rating>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
								<durModifier>nocode</durModifier>
								<dur/>
								<durUnit>nocode</durUnit>
								<timeFrame>nocode</timeFrame>
							</treatmentLine>
						</treatment>
					</preferredTherapy>
				</criteriaSet>
			</concurrenttherapy>
			<triedtherapy>
				<criteriaSet>
					<patientHxType>
						<typeName>all</typeName>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
							</treatmentLine>
						</treatment>
					</patientHxType>
					<preferredTherapy>
						<numRequired>any</numRequired>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
								<durModifier>nocode</durModifier>
								<dur/>
								<durUnit>nocode</durUnit>
								<timeFrame>nocode</timeFrame>
								<numRequired>any</numRequired>
							</treatmentLine>
							<mustBeIneligible>false</mustBeIneligible>
							<documentationRequired>false</documentationRequired>
						</treatment>
					</preferredTherapy>
				</criteriaSet>
			</triedtherapy>
			<triedTherapyExclusion>
				<criteriaSet>
					<excludedTherapy>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
								<timeFrame>nocode</timeFrame>
							</treatmentLine>
						</treatment>
					</excludedTherapy>
				</criteriaSet>
			</triedTherapyExclusion>
			<concurrentTherapyExclusion>
				<criteriaSet>
					<excludedTherapy>
						<treatment>
							<treatmentLine>
								<option>WITH</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
							</treatmentLine>
						</treatment>
					</excludedTherapy>
				</criteriaSet>
			</concurrentTherapyExclusion>
			<dosing>
				<text/>
			</dosing>
			<instructions>
				<instruction/>
			</instructions>
			<qlimits>
				<qlimit>
					<medId/>
					<initPerDayDesc/>
					<initPerIntervalDesc/>
					<renewPerDayDesc/>
					<renewPerIntervalDesc/>
				</qlimit>
			</qlimits>
			<durations>
				<initialDur>
					<dur/>
					<durUnit>nocode</durUnit>
				</initialDur>
				<renewalDur>
					<dur/>
					<durUnit>nocode</durUnit>
				</renewalDur>
				<overallMax>
					<dur/>
					<durUnit>nocode</durUnit>
				</overallMax>
			</durations>
			<references>
				<reference>Schoels MM, et al. Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement. Annals of the Rheumatic Diseases 2013;72(4):583-9. DOI: 10.1136/annrheumdis-2012-202470.</reference>
			</references>
			<precautions>
				<precaution>
					<text/>
					<severity/>
				</precaution>
			</precautions>
			<alternatives>
			</alternatives>
		</diagnosis>
	</diagnoses>
	<precautions>
		<geriatric>
			<caution>
				<drug/>
				<severity/>
				<text/>
			</caution>
		</geriatric>
		<pregnancy>
			<caution>
				<drug/>
				<severity/>
				<text/>
			</caution>
		</pregnancy>
		<pediatric>
			<caution>
				<drug/>
				<severity/>
				<text/>
			</caution>
		</pediatric>
		<lactation>
			<caution>
				<drug/>
				<severity/>
				<text/>
			</caution>
		</lactation>
		<allergy>
			<caution>
				<drug/>
				<severity/>
				<text/>
			</caution>
		</allergy>
		<sideEffect>
			<caution>
				<drug/>
				<severity/>
				<text/>
			</caution>
		</sideEffect>
		<drugDisease>
			<caution>
				<drug/>
				<severity/>
				<text/>
			</caution>
		</drugDisease>
	</precautions>
	<lists>
	</lists>
</paload>
